Search Results

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

• Authors : Holst, Jens Juul¹ (AUTHOR)

Subjects: GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide-1 agonists; TYPE 2 diabetes

• Source: Lancet. Jul2019, Vol. 394 Issue 10192, p4-6. 3p.

Record details

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

• Authors : Mafham, Marion¹; Preiss, David¹

Subjects: GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide-1 agonists; CARDIOVASCULAR disease treatmentGLAXOSMITHKLINEHERNANDEZ, Adrian

• Source: Lancet. 10/27/2018, Vol. 392 Issue 10157, p1489-1490. 2p.

Record details

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

• Authors : Pablo Frias, Juan; Nauck, Michael A.; Van, Joanna

Subjects: GLUCAGON-like peptide-1 receptor; GLUCAGON-like peptide 1; TYPE 2 diabetes treatment

• Source: Lancet. 11/17/2018, Vol. 392 Issue 10160, p2180-2193. 14p.

Record details

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

• Authors : Harmony Outcomes committees and investigators; Hernandez, Adrian F.; Green, Jennifer B.

Subjects: GLUCAGON-like peptide-1 receptor; TYPE 2 diabetes risk factors; CARDIOVASCULAR disease prevention

• Source: Lancet. 10/27/2018, Vol. 392 Issue 10157, p1519-1529. 11p.

Record details

Type 2 diabetes: which drug as add-on to metformin?

• Authors : Madsbad, Sten¹

Subjects: GLUCAGON-like peptide-1 receptor; TYPE 2 diabetes; INSULIN

• Source: Lancet. 6/16/2012, Vol. 379 Issue 9833, p2222-2223. 2p.

Record details

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

• Authors : Garvey, W Timothy (AUTHOR); Frias, Juan P (AUTHOR); Jastreboff, Ania M (AUTHOR)

Subjects: ELI Lilly & Co.; TYPE 2 diabetes; CLINICAL trials

• Source: Lancet. Aug2023, Vol. 402 Issue 10402, p613-626. 14p.

Record details

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

• Authors : Drucker DJ (AUTHOR); Nauck MA (AUTHOR)

• Source: Lancet. 11/11/2006, Vol. 368 Issue 9548, p1696-1705. 10p.

Record details

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.

• Authors : Eng, Conrad; Kramer, Caroline K.; Zinman, Bernard

Subjects: PROGLUCAGON; PANCREATIC secretions; PEPTIDE hormones

• Source: Lancet. 12/20/2014, Vol. 384 Issue 9961, p2228-2234. 7p.

Record details

Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?

• Authors : Rayner, Christopher K.; Horowitz, Michael

Subjects: PEPTIDE hormones; TYPE 2 diabetes; BARIATRIC surgery

• Source: Lancet. 6/30/2018, Vol. 391 Issue 10140, p2577-2578. 2p. 1 Color Photograph.

Record details

Choosing a blood-glucose-lowering agent after metformin.

• Authors : Diamant, Michaela

Subjects: METFORMIN; TREATMENT of diabetes; BLOOD sugar

• Source: Lancet. 6/16/2012, Vol. 379 Issue 9833, p2220-2221. 2p.

Record details